312 related articles for article (PubMed ID: 15533050)
1. Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions.
Porat Y; Mazor Y; Efrat S; Gazit E
Biochemistry; 2004 Nov; 43(45):14454-62. PubMed ID: 15533050
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis.
Jaikaran ET; Higham CE; Serpell LC; Zurdo J; Gross M; Clark A; Fraser PE
J Mol Biol; 2001 May; 308(3):515-25. PubMed ID: 11327784
[TBL] [Abstract][Full Text] [Related]
3. Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties.
Tenidis K; Waldner M; Bernhagen J; Fischle W; Bergmann M; Weber M; Merkle ML; Voelter W; Brunner H; Kapurniotu A
J Mol Biol; 2000 Jan; 295(4):1055-71. PubMed ID: 10656810
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic beta-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation.
Jaikaran ET; Nilsson MR; Clark A
Biochem J; 2004 Feb; 377(Pt 3):709-16. PubMed ID: 14565847
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of hIAPP amyloid-fibril formation and apoptotic cell death by a designed hIAPP amyloid- core-containing hexapeptide.
Tatarek-Nossol M; Yan LM; Schmauder A; Tenidis K; Westermark G; Kapurniotu A
Chem Biol; 2005 Jul; 12(7):797-809. PubMed ID: 16039527
[TBL] [Abstract][Full Text] [Related]
6. Islet amyloid polypeptide inserts into phospholipid monolayers as monomer.
Engel MF; Yigittop H; Elgersma RC; Rijkers DT; Liskamp RM; de Kruijff B; Höppener JW; Antoinette Killian J
J Mol Biol; 2006 Feb; 356(3):783-9. PubMed ID: 16403520
[TBL] [Abstract][Full Text] [Related]
7. The minimal amyloid-forming fragment of the islet amyloid polypeptide is a glycolipid-binding domain.
Levy M; Garmy N; Gazit E; Fantini J
FEBS J; 2006 Dec; 273(24):5724-35. PubMed ID: 17212787
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism.
Porat Y; Abramowitz A; Gazit E
Chem Biol Drug Des; 2006 Jan; 67(1):27-37. PubMed ID: 16492146
[TBL] [Abstract][Full Text] [Related]
9. Impaired processing of human pro-islet amyloid polypeptide is not a causative factor for fibril formation or membrane damage in vitro.
Khemtémourian L; Lahoz Casarramona G; Suylen DP; Hackeng TM; Meeldijk JD; de Kruijff B; Höppener JW; Killian JA
Biochemistry; 2009 Nov; 48(46):10918-25. PubMed ID: 19817482
[TBL] [Abstract][Full Text] [Related]
10. Phenolsulfonphthalein, but not phenolphthalein, inhibits amyloid fibril formation: implications for the modulation of amyloid self-assembly.
Levy M; Porat Y; Bacharach E; Shalev DE; Gazit E
Biochemistry; 2008 Jun; 47(22):5896-904. PubMed ID: 18457421
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus.
Lorenzo A; Razzaboni B; Weir GC; Yankner BA
Nature; 1994 Apr; 368(6473):756-60. PubMed ID: 8152488
[TBL] [Abstract][Full Text] [Related]
12. Aromatic interactions are not required for amyloid fibril formation by islet amyloid polypeptide but do influence the rate of fibril formation and fibril morphology.
Marek P; Abedini A; Song B; Kanungo M; Johnson ME; Gupta R; Zaman W; Wong SS; Raleigh DP
Biochemistry; 2007 Mar; 46(11):3255-61. PubMed ID: 17311418
[TBL] [Abstract][Full Text] [Related]
13. The effect of apolipoprotein E deficiency on islet amyloid deposition in human islet amyloid polypeptide transgenic mice.
Vidal J; Verchere CB; Andrikopoulos S; Wang F; Hull RL; Cnop M; Olin KL; LeBoeuf RC; O'Brien KD; Chait A; Kahn SE
Diabetologia; 2003 Jan; 46(1):71-9. PubMed ID: 12637985
[TBL] [Abstract][Full Text] [Related]
14. Structural polymorphism of human islet amyloid polypeptide (hIAPP) oligomers highlights the importance of interfacial residue interactions.
Zhao J; Yu X; Liang G; Zheng J
Biomacromolecules; 2011 Jan; 12(1):210-20. PubMed ID: 21158384
[TBL] [Abstract][Full Text] [Related]
15. Design of peptide-based inhibitors of human islet amyloid polypeptide fibrillogenesis.
Scrocchi LA; Chen Y; Waschuk S; Wang F; Cheung S; Darabie AA; McLaurin J; Fraser PE
J Mol Biol; 2002 May; 318(3):697-706. PubMed ID: 12054816
[TBL] [Abstract][Full Text] [Related]
16. Rifampicin does not prevent amyloid fibril formation by human islet amyloid polypeptide but does inhibit fibril thioflavin-T interactions: implications for mechanistic studies of beta-cell death.
Meng F; Marek P; Potter KJ; Verchere CB; Raleigh DP
Biochemistry; 2008 Jun; 47(22):6016-24. PubMed ID: 18457428
[TBL] [Abstract][Full Text] [Related]
17. Ganglioside-induced amyloid formation by human islet amyloid polypeptide in lipid rafts.
Wakabayashi M; Matsuzaki K
FEBS Lett; 2009 Sep; 583(17):2854-8. PubMed ID: 19647738
[TBL] [Abstract][Full Text] [Related]
18. The generic amyloid formation inhibition effect of a designed small aromatic β-breaking peptide.
Frydman-Marom A; Shaltiel-Karyo R; Moshe S; Gazit E
Amyloid; 2011 Sep; 18(3):119-27. PubMed ID: 21651439
[TBL] [Abstract][Full Text] [Related]
19. Association of highly compact type II diabetes related islet amyloid polypeptide intermediate species at physiological temperature revealed by diffusion NMR spectroscopy.
Soong R; Brender JR; Macdonald PM; Ramamoorthy A
J Am Chem Soc; 2009 May; 131(20):7079-85. PubMed ID: 19405534
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal ultrastructure study of islet amyloid in the HIP rat model of type 2 diabetes mellitus.
Hayden MR; Karuparthi PR; Manrique CM; Lastra G; Habibi J; Sowers JR
Exp Biol Med (Maywood); 2007 Jun; 232(6):772-9. PubMed ID: 17526769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
